Table of Contents
| << Previous Issue | Feb 2026 (Vol: 2026, Issue: 2) |
- Section: Research & Development
-
Boehringer Ingelheim and Simcere Forge US$1.26 B Collaboration to Advance Inflammatory Bowel Disease Bispecific Antibody
-
Lilly Signs US$1.9 B Global Collaboration with Repertoire for Autoimmune Diseases
-
AstraZeneca Signs US$18.5 B Licensing Pact with CSPC Pharmaceutical Group for Obesity and Type 2 Diabetes Treatments
-
Lilly Signs US$8.85 B Oncology and Immunology Partnership with Innovent Biologics



RSS